A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease

Summary

This study evaluates the efficacy and safety of tetrandrine tablets (60 mg, three times daily) compared to placebo in adult patients with connective tissue disease-related interstitial lung disease. Patients receive standard treatment (glucocorticoids and immunosuppressants) alongside the study drug or placebo for 24 weeks. The study measures changes in lung function, inflammatory markers, lung imaging, quality of life, and safety outcomes.

Timeline

Start

2023-11-02

Primary completion

2026-10-15

Completion

2027-01-01

Drugs

Indications